For 40 years, it has been the standard in post-heart attack health care, but a new study from the European Society of Cardiology is putting the usage of beta blockers in limbo. While the new study may ...

For over four decades, many heart attack survivors have been sent home with a prescription for beta-blockers, which are drugs that impact the effects of hormones and adrenaline on the heart and blood ...

Two new studies point in opposite directions. A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide ...

New American guidelines for chronic coronary disease (CCD) modify management considerations for a heterogeneous group that includes people with or without angina, a history of coronary ...

A collaborative effort among international research teams provides the most definitive statement yet on the usefulness of ...

ATLANTA — Beta blockers are a mainstay in cardiovascular treatment, frequently given to patients after heart attacks. But a new large trial turns that convention on its head, suggesting that the drugs ...

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR ...

A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn’t benefit the vast majority of patients and may contribute to a higher risk of ...